Who owns SUTRO BIOPHARMA, INC.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from SEC filings.
Institutional ownership of STRO from SEC Form 13F filings across 75 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 75 institutions disclosed 7.9M shares of SUTRO BIOPHARMA, INC. worth $248.7M — about 47.5% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
75
13F holders
$248.7M
value, 2026 filers
47.5%
of shares outstanding (7.9M sh)
34
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30· % of fund = share of the manager's own book · % of co. = share of STRO's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 1.1M | $37.3M | 0.0% | 6.8% | +382.5% |
| 2 | ORBIMED ADVISORS LLC | 743,944 | $24.7M | 0.5% | 4.5% | -7.1% |
| 3 | Balyasny Asset Management L.P. | 711,162 | $23.6M | 0.0% | 4.3% | +52.7% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 694,219 | $23.0M | 0.0% | 4.2% | -51.8% |
| 5 | Woodline Partners LP | 458,029 | $15.2M | 0.0% | 2.8% | -49.9% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 389,692 | $12.9M | 0.0% | 2.4% | +127.4% |
| 7 | ACADIAN ASSET MANAGEMENT LLC | 373,839 | $12,405 | 0.0% | 2.3% | +11.3% |
| 8 | MILLENNIUM MANAGEMENT LLC | 365,972 | $12.2M | 0.0% | 2.2% | +74.0% |
| 9 | AMERIPRISE FINANCIAL INCNEW | 244,669 | $8.1M | 0.0% | 1.5% | new |
| 10 | Point72 Asset Management, L.P. | 237,827 | $7.9M | 0.0% | 1.4% | -65.6% |
| 11 | UBS Group AG | 208,512 | $6.9M | 0.0% | 1.3% | -46.9% |
| 12 | TWO SIGMA INVESTMENTS, LP | 201,688 | $6.7M | 0.0% | 1.2% | +209.5% |
| 13 | VANGUARD PORTFOLIO MANAGEMENT LLCNEW | 197,562 | $6.6M | 0.0% | 1.2% | new |
| 14 | MARSHALL WACE, LLP | 175,246 | $5.8M | 0.0% | 1.1% | -21.3% |
| 15 | Nuveen, LLCNEW | 167,997 | $5.6M | 0.0% | 1% | new |
| 16 | JPMORGAN CHASE & CONEW | 159,627 | $5.3M | 0.0% | 1% | new |
| 17 | GOLDMAN SACHS GROUP INC | 149,216 | $5.0M | 0.0% | 0.9% | +448.9% |
| 18 | NORTHERN TRUST CORP | 125,933 | $4.2M | 0.0% | 0.8% | +279.7% |
| 19 | Qube Research & Technologies LtdNEW | 106,610 | $3.5M | 0.0% | 0.6% | new |
| 20 | VANGUARD FIDUCIARY TRUST CO | 104,232 | $3.5M | 0.0% | 0.6% | +9.9% |
| 21 | CITADEL ADVISORS LLC | 101,965 | $3.4M | 0.0% | 0.6% | -13.2% |
| 22 | MACKENZIE FINANCIAL CORPNEW | 94,767 | $3.1M | 0.0% | 0.6% | new |
| 23 | Invesco Ltd. | 57,305 | $1.9M | 0.0% | 0.3% | +233.8% |
| 24 | Y-Intercept (Hong Kong) LtdNEW | 55,879 | $1.9M | 0.0% | 0.3% | new |
| 25 | Squarepoint Ops LLCNEW | 55,539 | $1.8M | 0.0% | 0.3% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.